Hyponatremia at Hemodialysis Initiation Increases Death Risk Nationally standardized treatment algorithms for hyperkalemia should be developed, according to investigators. The following article ...

Synthetic ion-exchange resins were first made available to industry in 1935 and have since been extensively adapted to . . . From the Cardio-Renal Laboratory, Second (Cornell) Medical Division, ...

Chronic kidney disease affects approximately 850 million people globally, with hyperkalemia representing a disproportionately high burden in this population¹. While hyperkalemia occurs in only 2-3% of ...

New findings have important implications in the new era where delaying dialysis initiation is a priority goal by means of continued conservative management of hyperkalemia, according to investigators.

MINNEAPOLIS — A reduced risk for death may balance out concerns about hyperkalemia when treating heart failure with renin-angiotensin system (RAS) inhibitors and mineralocorticoid receptor antagonists ...

Those with chronic kidney disease, heart failure, diabetes, and hypertension bear an increased burden of hyperkalemia. Untreated hyperkalemia can lead to life-threatening neuromuscular and cardiac ...

"Identifying the causes of ambulatory care-sensitive condition hospitalizations will help [in] formulating policies for effective and focused outpatient management for patients with CKD and in turn ...

Patients taking renin-angiotensin-aldosterone system inhibitor (RAASi) medications for heart failure had significantly lower blood potassium levels when taking patiromer—a drug that helps to prevent ...

Please provide your email address to receive an email when new articles are posted on . In addition to being male and of older age, being Black or Hispanic can increase a patient’s risk for ...

Please provide your email address to receive an email when new articles are posted on . Fewer patients with hyperkalemia were prescribed renin-angiotensin-aldosterone system inhibitors for HF.

WASHINGTON, DC—The oral potassium-binding agent patiromer (Veltassa; Vifor Pharma) may help keep hyperkalemia under control in heart failure with reduced ejection fraction (HFrEF) patients taking ...

Special Late-Breaking Clinical Science Abstract: Effects of Anti-Inflammatory Therapy in Acute Heart Failure: A Systematic Review and Meta-Analysis Receive the the latest news, research, and ...